Liver Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Journal
Journal of computer assisted tomography
ISSN: 1532-3145
Titre abrégé: J Comput Assist Tomogr
Pays: United States
ID NLM: 7703942
Informations de publication
Date de publication:
27 Feb 2024
27 Feb 2024
Historique:
medline:
5
3
2024
pubmed:
5
3
2024
entrez:
4
3
2024
Statut:
aheadofprint
Résumé
The incidence of neuroendocrine neoplasms (NENs) has gradually increased over the past few decades with the majority of patients presenting with metastases on initial presentation. The liver is the most common site of initial metastatic disease, and the presence of liver metastasis is an independent prognostic factor associated with a negative outcome. Because NENs are heterogenous neoplasms with variable differentiation, grading, and risk of grade transformation over time, accurate diagnosis and management of neuroendocrine liver lesions are both important and challenging. This is particularly so with the multiple liver-directed treatment options available. In this review article, we discuss the diagnosis, treatment, and response evaluation of NEN liver metastases.
Identifiants
pubmed: 38438332
doi: 10.1097/RCT.0000000000001576
pii: 00004728-990000000-00289
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Lee MR, Harris C, Baeg KJ, et al. Incidence trends of gastroenteropancreatic neuroendocrine tumors in the United States. Clin Gastroenterol Hepatol. 2019;17:2212–2217.e1.
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342.
Maxwell JE, O'Dorisio TM, Howe JR. Biochemical diagnosis and preoperative imaging of Gastroenteropancreatic neuroendocrine tumors. Surg Oncol Clin N Am. 2016;25:171–194.
Davies L, Weickert MO. Gastroenteropancreatic neuroendocrine tumours: an overview. Br J Nurs. 2016;25:S12–S15.
Scigliano S, Lebtahi R, Maire F, et al. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocr Relat Cancer. 2009;16:977–990.
Kimbrough CW, Beal EW, Dillhoff ME, et al. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. Surgery. 2019;165:657–663.
Laskaratos FM, Davar J, Toumpanakis C. Carcinoid heart disease: a review. Curr Oncol Rep. 2021;23:48.
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–188.
Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31:1770–1786.
Lewis MA, Thompson GB, Young WF Jr. Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1. World J Surg. 2012;36:1375–1381.
Ambrosini V, Kunikowska J, Baudin E, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56–73.
Sundin A, Arnold R, Baudin E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological nuclear medicine & hybrid imaging. Neuroendocrinology. 2017;105:212–244.
D'Onofrio M, Crosara S, De Robertis R, et al. Contrast-enhanced ultrasound of focal liver lesions. AJR Am J Roentgenol. 2015;205:W56–W66.
Abdulrezzak U, Kurt YK, Kula M, et al. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. Nucl Med Commun. 2016;37:874–881.
Walczyk J, Sowa-Staszczak A. Diagnostic imaging of gastrointestinal neuroendocrine neoplasms with a focus on ultrasound. J Ultrason. 2019;19:228–235.
Braden B, Jenssen C, D'Onofrio M, et al. B-mode and contrast-enhancement characteristics of small nonincidental neuroendocrine pancreatic tumors. Endosc Ultrasound. 2017;6:49–54.
Kos-Kudła B, Blicharz-Dorniak J, Strzelczyk J, et al. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the polish network of neuroendocrine tumours). Endokrynol Pol. 2017;68:79–110.
Ronot M, Cuccioli F, Burgio MD, et al. Neuroendocrine liver metastases: vascular patterns on triple-phase MDCT are indicative of primary tumour location. Eur J Radiol. 2017;89:156–162.
Armstrong EA, Beal EW, Shah M, et al. Radiographic characteristics of neuroendocrine liver metastases do not predict clinical outcomes following liver resection. Hepatobiliary Surg Nutr. 2020;9:1–12.
Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23:70–78.
Danet I-M, Semelka RC, Leonardou P, et al. Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol. 2003;181:809–817.
d'Assignies G, Fina P, Bruno O, et al. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology. 2013;268:390–399.
Lotfalizadeh E, Ronot M, Wagner M, et al. Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. Eur Radiol. 2017;27:1748–1759.
Hayoz R, Vietti-Violi N, Duran R, et al. The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. Eur Radiol. 2020;30:6593–6602.
Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007;188:1622–1635.
Kulali F, Semiz-Oysu A, Demir M, et al. Role of diffusion-weighted MR imaging in predicting the grade of nonfunctional pancreatic neuroendocrine tumors. Diagn Interv Imaging. 2018;99:301–309.
Thang SP, Lung MS, Kong G, et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) — a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging. 2018;45:262–277.
Ambrosini V, Campana D, Bodei L, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51:669–673.
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–135.
Kim YI, Yoo C, Oh SJ, et al. Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Res. 2020;10:63.
Fard N, Schlemmer H-P, Raue F, et al. CT- and ultrasound-characteristics of hepatic lesions in patients with multiple endocrine neoplasia syndrome. A retrospective image review of 25 cases. PLoS One. 2019;14:e0212865.
Calabrò D, Argalia G, Ambrosini V. Role of PET/CT and therapy management of pancreatic neuroendocrine tumors. Diagnostics (Basel). 2020;10:1059.
Binderup T, Knigge U, Johnbeck CB, et al. (18)F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study. J Nucl Med. 2021;62:808–815.
Ninatti G, Duan H, Ferri V, et al. Pulmonary large cell neuroendocrine carcinoma (LCNEC) with confirmed liver metastases negative on (18)F-FDG and (68)Ga-DOTATATE PET. Radiol Case Rep. 2020;15:2698–2700.
Zhang P, Yu J, Li J, et al. Clinical and prognostic value of PET/CT imaging with combination of 68Ga-DOTATATE and 18F-FDG in gastroenteropancreatic neuroendocrine neoplasms. Contrast Media Mol Imaging. 2018;2018:2340389.
Refardt J, Hofland J, Wild D, et al. New directions in imaging neuroendocrine neoplasms. Curr Oncol Rep. 2021;23:143.
Bodei L, Weber WA. Somatostatin receptor imaging of neuroendocrine tumors: from agonists to antagonists. J Nucl Med. 2018;59:907–908.
Murakami T, Tsurusaki M. Hypervascular benign and malignant liver tumors that require differentiation from hepatocellular carcinoma: key points of imaging diagnosis. Liver Cancer. 2014;3:85–96.
Hayes AR, Crawford A, Al Riyami K, et al. Metastatic medullary thyroid Cancer: the role of 68Gallium-DOTA-somatostatin analogue PET/CT and peptide receptor radionuclide therapy. J Clin Endocrinol Metab. 2021;106:e4903–e4916.
Kaltenbach B, Wichmann JL, Pfeifer S, et al. Iodine quantification to distinguish hepatic neuroendocrine tumor metastasis from hepatocellular carcinoma at dual-source dual-energy liver CT. Eur J Radiol. 2018;105:20–24.
Werner RA, Ilhan H, Lehner S, et al. Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2019;21:582–590.
Liberini V, Rampado O, Gallio E, et al. 68Ga-DOTATOC PET/CT-based radiomic analysis and PRRT outcome: a preliminary evaluation based on an exploratory radiomic analysis on two patients. Front Med (Lausanne). 2020;7:601853.
Tirosh A, Papadakis GZ, Millo C, et al. Prognostic utility of total 68Ga-DOTATATE-Avid tumor volume in patients with neuroendocrine tumors. Gastroenterology. 2018;154:998–1008.e1.
Toriihara A, Baratto L, Nobashi T, et al. Prognostic value of somatostatin receptor expressing tumor volume calculated from (68)Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46:2244–2251.
Weber M, Kessler L, Schaarschmidt B, et al. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from (68)Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. BMC Cancer. 2020;20:326.
Perysinakis I, Aggeli C, Kaltsas G, et al. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality? Hormones (Athens). 2016;15:15–22.
Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39:799–800.
Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:839–868.
Li G, Tian M-L, Bing Y-T, et al. Clinicopathological features and prognosis factors for survival in elderly patients with pancreatic neuroendocrine tumor: a STROBE-compliant article. Medicine (Baltimore). 2019;98:e14576.
Devcic Z, Rosenberg J, AJA Braat, et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med. 2014;55:1404–1410.
Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007;47:460–466.
Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557–577.
Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–176.
Steinmüller T, Kianmanesh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87:47–62.
Cloyd JM, Ejaz A, Konda B, et al. Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surg Nutr. 2020;9:440–451.
O'Toole D, Kianmanesh R, Caplin M. ENETS 2016 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology. 2016;103:117–118.
Galleberg RB, Knigge U, Tiensuu Janson E, et al. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. Eur J Surg Oncol. 2017;43:1682–1689.
May BJ, Madoff DC. Portal vein embolization: rationale, technique, and current application. Semin Intervent Radiol. 2012;29:81–89.
Ronot M, Clift AK, Baum RP, et al. Morphological and functional imaging for detecting and assessing the resectability of neuroendocrine liver metastases. Neuroendocrinology. 2018;106:74–88.
Gibril F, Jensen RT. Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors. Yale J Biol Med. 1997;70(5–6):509–522.
Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133:375–382.
Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163:218–225.
Yu X, Gu J, Wu H, et al. Resection of liver metastases: a treatment provides a long-term survival benefit for patients with advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Oncol. 2018;2018:6273947.
Tran CG, Sherman SK, Chandrasekharan C, et al. Surgical management of neuroendocrine tumor liver metastases. Surg Oncol Clin N Am. 2021;30:39–55.
Mayo SC, Herman JM, Cosgrove D, et al. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg. 2013;216:123–134.
Taner T, Atwell TD, Zhang L, et al. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. HPB (Oxford). 2013;15:190–195.
Mazzaglia PJ, Berber E, Milas M, et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142:10–19.
Sartori S, Bianchi L, Di Vece F, et al. Liver-directed therapies for liver metastases from neuroendocrine neoplasms: can laser ablation play any role? World J Gastroenterol. 2020;26:3118–3125.
Kessler J, Singh G, PHG Ituarte, et al. A comparison of liver-directed therapy and systemic therapy for the treatment of liver metastases in patients with gastrointestinal neuroendocrine tumors: analysis of the California Cancer registry. J Vasc Interv Radiol. 2021;32:393–402.
Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271–279.
Kennedy A, Bester L, Salem R, et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-liver-metastases consensus conference. HPB (Oxford). 2015;17:29–37.
Braat A, Ahmadzadehfar H, Kappadath SC, et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy. Cardiovasc Intervent Radiol. 2020;43:246–253.
Galgano SJ, Iravani A, Bodei L, et al. Imaging of neuroendocrine neoplasms: monitoring treatment response-AJR expert panel narrative review. AJR Am J Roentgenol. 2022;218:767–780.
Campana D, Ambrosini V, Pezzilli R, et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51:353–359.
Gabriel M, Oberauer A, Dobrozemsky G, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427–1434.
Kose E, Kahramangil B, Aydin H, et al. Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience. Surg Endosc. 2020;34:249–256.